My take:
Vagif,Alexander,Ian,Darren and SLA's patent specialist all spoke.....well ....
Essentially the strategy is to
1. make a profit (2016/7) by providing raw product ( CGNC mostly) to suppliers who will value add. ( I counted 8+ “partnersâ€ÂÂÂÂÂ) ….giving shareholders some confidence
2. remarket SLA finished products in various locations ,using various methods.
then
3. focus on pharma level claims for Ropren ( and others Bios) .
Darren, publically, was confident of the products but was frustrated by the inconsistent research ( not the results) that made it hard to present a case for the products at registration level
Ian will become Chair when the company is cash flow positive
Presentation on Patents was very positive and professional
There has been massive dilution ,to be fair to SLA they seem to have done a lot with that $19 mill… both tiding it up and adding value,…..the company is viable now…..…but that comes with the biotech industry any way.
An IPO is on the way,this will create further dilution.